Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transcend FL trial of lisocabtagene maraleucel in relapsed or refractory indolent B-cell non-Hodgkin lymphoma
2024-510966-18-00Phase 2Authorised
- Sponsor
- Celgene Corporation
- Start
- Jun 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 9
01
Overview
Phase 2, open-label trial of lisocabtagene maraleucel in follicular lymphoma (FL), marginal zone B-cell lymphoma (MZL) and mature B-cell lymphoma (5 cohorts), sponsored by Celgene Corporation. Primary endpoint: Overall response rate. Planned start Jun 2024; status: authorised.
02
Drugs
lisocabtagene maraleucel
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2024-510966-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510966-18-00.